Opioid and opioid-like compounds and uses thereof
The present invention relates to opioid and opioid-like compounds, and pharmaceutical formulations thereof, and use thereof for prevention and treatment of disorders such as septic shock and organ damage.
1. A method for treating an infection caused by hepatitis B virus comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of naltrexone.
2. A method for treating an infection caused by hepatitis B virus comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of nalmefene.
3. A method for treating liver damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of naltrexone and measuring the decrease of at least one of the enzymes SGOT and SGPT in the subject being treated.
4. A method for treating liver damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of nalmefene and measuring the decrease of at least one of the enzymes SGOT and SGPT in the subject being treated.
5. A method for treating kidney damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of naltrexone and measuring the decrease of at least one of blood urine nitrogen and creatinine levels in the subject being treated.
6. A method for treating kidney damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of nalmefene and measuring the decrease of at least one of blood urine nitrogen and creatinine levels in the subject being treated.
7. A method as claimed in claim 3 for treating liver damage caused by alcohol abuse, bacterial infection or environmental toxins comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of naltrexone.
8. A method as claimed in claim 4 for for treating liver damage caused by alcohol abuse, bacterial infection or environmental toxins comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of nalmefene.
9. A method as claimed in claim 5 for treating kidney damage caused by alcohol abuse, bacterial infection or environmental toxins comprising administering to a subject in need thereof, a pharmaceutical composition comprising a therapeutically effective amount of naltrexone.
10. A method as claimed in claim 6 for treating kidney damage caused by alcohol abuse, bacterial infection or environmental toxins comprising administering to a subject in need thereof; a pharmaceutical composition comprising a therapeutically effective amount of nalmefene.
11. A method according to claim 3 for treating liver damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a daily dose of from 2 mg to 100 mg of naltrexone and measuring the decrease of at least one of the enzymes SGOT and SGPT in the subject being treated.
12. A method according to claim 4 for treating liver damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a daily dose of from 2 mg to 100 mg of nalmefene and measuring the decrease of at least one of the enzymes SGOT and SGPT in the subject being treated.
13. A method as claimed in claim 5 for treating kidney damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a daily dose of from 2 mg to 100 mg of naltrexone and measuring the decrease of at least one of blood urine nitrogen and creatinine levels in the subject being treated.
14. A method as claimed in claim 6 for treating kidney damage comprising administering to a subject in need thereof, a pharmaceutical composition comprising a daily dose of from 2 mg to 100 mg of nalmefene and measuring the decrease of at least one of blood urine nitrogen and creatinine levels in the subject being treated.
15. The method according to claim 1 , 2 , 3 , 4 , 5 or 6 , wherein the pharmaceutical composition is administered orally.
16. The method according to claim 1 , 2 , 3 , 4 , 5 or 6 wherein the pharmaceutical composition is administered parenterally.